No. HB 1335
Filed under Healthcare.
Newborn Screenings; Requires, beginning on specified date, that newborns to be screened for biliary atresia; requires DOH to consult with Genetics & Newborn Screening Advisory Council before adopting certain rules; requires department, by specified date, to implement certain education campaign relating to biliary atresia.
Plain English Summary
AI-GENERATEDStarting January 1, 2027, every newborn in Florida must be screened for biliary atresia, a serious liver condition, added to the existing state-mandated newborn testing panel that already screens for certain metabolic and genetic disorders.
Unlike the Duchenne muscular dystrophy screening added elsewhere in this same law, the biliary atresia requirement is not conditioned on the Legislature appropriating money for it.
By October 1, 2026, the health department must launch a statewide education campaign teaching new and expecting parents the symptoms of biliary atresia and training doctors, osteopaths, and nurses to spot it early.
The department no longer has to consult the state's Genetics and Newborn Screening Advisory Council before every newborn-screening rule -- only before rules on screening methods, follow-up procedures, or adding new conditions to test for.
AIAdds a new, unconditional requirement that every newborn in Florida be tested for biliary atresia beginning January 1, 2027, as part of the state's mandatory newborn screening panel.
AIRequires the health department to implement a statewide public-health education campaign by October 1, 2026 to raise awareness of biliary atresia, months before the screening mandate itself takes effect.
AIThe education campaign must specifically give physicians, osteopathic physicians, and nurses licensed in Florida guidance on identifying biliary atresia in infants and on the risks of delayed treatment.
AIRemoves the requirement to consult the Genetics and Newborn Screening Advisory Council before adopting any newborn-screening rule, replacing it with a narrower duty to consult only before rules on screening methods, follow-up procedures, or adding new conditions to the program.